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: Crimes and Offenses SB 36

CRIMES AND OFFENSES
Controlled Substances: Amend Chapter 13 of Title 16 and Chapter
4 of Title 26 of the Official Code of Georgia Annotated, Relating to
Controlled Substances and Pharmacists and Pharmacies,
Respectively, so as to Implement Various Measures Relating to the
Regulation and Security of Prescribing and Dispensing Controlled
Substances; Provide for the Establishment of a Program to Monitor
the Prescribing and Dispensing of Schedule II, III, IV, and V
Controlled Substances; Provide for Definitions; Require Dispensers
to Submit Certain Information Regarding the Dispensing of Such
Controlled Substances; Provide for the Confidentiality of Submitted
Information Except under Certain Circumstances; Provide for the
Establishment of an Electronic Database Review Advisory
Committee; Provide for Its Membership, Duties, and Organization;
Provide for the Establishment of Rules and Regulations; Provide
for Limited Liability; Provide for Penalties; Require that Hard
Copy Prescriptions for Schedule II Controlled Substances Be on
Security Paper; Redefine the Term “Security Paper” and Provide
for Approval of Such Paper Prior to Sale by the State Board of
Pharmacy; Provide for Exceptions; Provide for Rules and
Regulations; Require Identification from Persons Picking Up
Certain Prescriptions; Provide for Related Matters; Provide for an
Effective Date; Repeal Conflicting Laws; and for Other Purposes.
CODE SECTIONS:

BILL NUMBER:
ACT NUMBER:
GEORGIA LAWS:
SUMMARY:

O.C.G.A. §§ 16-13-21 (amended), -57
(new), -58 (new), -59 (new), -60 (new),
-61 (new), -62 (new), -63 (new), -64
(new), -65 (new); 26-4-5 (amended);
26-4-80.1 (new); 26-4-80.2 (new)
SB 36
229
2011 Ga. Laws 659
The Act authorizes the Georgia Drugs
and Narcotics Agency to establish and
maintain a program to record and
monitor the prescription and dispensing
269
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of Schedule II, III, IV, and V controlled
substances.
It
provides
for
confidentiality of the submitted
information and establishes penalties
for the breach of these provisions. It
also provides for the establishment of
an Electronic Database Review
Advisory Committee and for its
membership. The Act requires that
Schedule II written prescriptions be on
security paper.
July 1, 2011

History
In recent years, Georgia has seen a dramatic increase in
prescription drug addiction.1 Bolstering this problem are “pill mills;”
comprised of pharmacies, doctors, or clinics that prescribe or
dispense painkillers inappropriately or for non-medical purposes, to
addicts and drug dealers, sometimes without even examining the
patient.2 These facilities prey on addicts, often accepting only cash
payments, refusing to take appointments, and failing to maintain
medical records.3 Georgia became a target for these rogue doctors,
pharmacists, addicts, and drug dealers because it was one of only
four states without legislation establishing a prescription drug
monitoring program.4 As a result, Georgia provided a safe harbor for
1. Senator Buddy Carter, the bill’s sponsor, described the situation in Georgia as an “epidemic.”
Interview with Sen. Buddy Carter (R-1st) (Mar. 29, 2011) [hereinafter Carter Interview] (on file with the
Georgia State University Law Review). “There were 584 prescription drug overdose deaths in Georgia
in 2009, according to records from the GBI Medical Examiner’s Office. By comparison, there were 86
deaths from illegal drug overdoses.” April Hunt & Andria Simmons, Trailing an Elusive Killer,
ATLANTA J.-CONST., May 7, 2011, at B2, available at http://www.ajc.com/news/georgia-politicselections/trailing-an-elusive-killer-938655.html.
2. Greg Bluestein, Feds in Ga. to Ramp up “Pill Mill” Investigations, ASSOCIATED PRESS, Feb. 28,
2011, available at http://abcnews.go.com/Business/wireStory?id=13020612&page=1; Pia Malbran,
What’s a Pill Mill?, CBS NEWS, May 31, 2007, http://www.cbsnews.com/8301-501263_162-2872835501263.html.
3. Bluestein, supra note 2.
4. As of spring 2011 Georgia, Maryland, Missouri, and New Hampshire all had prescription
monitoring program legislation pending. Status of Prescription Drug Monitoring Programs (map), The
Alliance
of
States
with
Prescription
Monitoring
Programs,
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these activities since each bordering state had enacted prescription
monitoring program legislation.5 This failure to pass legislation was
not due to a lack of trying; during the years preceding the passage of
Senate Bill (SB) 36, various forms of prescription monitoring
legislation were introduced in Georgia, but none were successful.6
Much of the opposition to these proposals arose out of concern for
patient privacy and funding.7
Because the majority of states have established prescription
monitoring databases, Georgia had many models upon which to base
its legislation. Many states include prescription monitoring for all
Schedule II, III, IV, and V controlled substances, while some have
limited the database to only Schedule II, III, or IV drugs.8 At a
minimum, all prescription monitoring programs include Schedule II
drugs and some have included specific substances rather than an
http://www.pmpalliance.org/pdf/pmpstatusmap2011.pdf (last visited June 12, 2011) [hereinafter Map of
States with Prescription Monitoring Programs]. Eleven states plus Guam have enacted legislation, but
their databases are not yet operational. Id. Thirty-five states have operational prescription drug
monitoring programs. Id.
5. Video Recording of House Judiciary Non-Civil Committee Proceedings, Mar. 28, 2011 at 6
min.,
10
sec.
(remarks
by
Sen.
Buddy
Carter
(R-1st)),
http://media.legis.ga.gov/hav/11_12/2011/committees/judiNon/judiNon032811EDITED.wmv
[hereinafter House Committee Video]; Map of States with Prescription Monitoring Programs, supra
note 4.
6. See HB 455, as introduced, 2008 Ga. Gen. Assem.; HB 614, as introduced, 2009 Ga. Gen.
Assem.; SB 418, as introduced, 2010 Ga. Gen. Assem.; HB 184, as introduced, 2010 Ga. Gen. Assem.
7. Senators
Reintroduce
Prescription
Drug
Monitoring
Act,
PEACHPUNDIT.COM,
http://www.peachpundit.com/2010/03/11/senators-reintroduce-prescription-drug-monitoring-act/ (Mar.
11, 2010); Database Would Track Prescriptions, AUGUSTA CHRON., Feb. 18, 2011, at A11, available at
http://chronicle.augusta.com/news/health/2011-02-18/database-would-track-prescriptions.
8. Controlled substances are divided into five schedules under 21 C.F.R. § 1308. Controlled
Substance Schedules, http://www.deadiversion.usdoj.gov/schedules/index.html#define (last visited June
12, 2011). A controlled substance is assigned to a schedule based on its currently accepted medical use
and its potential for abuse or addiction. Id. As the schedule numbers increase, generally the potential for
abuse decreases. Id. For example, Schedule II controlled substances have a high potential for abuse, but
have medically accepted uses, whereas Schedule V controlled substances have a low potential for abuse.
Id. Schedule I controlled substances are not included in the Prescription Monitoring Database because
they are substances with a very high potential for abuse and no medically accepted uses. Id.
Connecticut, Massachusetts, New York, Delaware, Alaska, Colorado, Hawaii, Idaho, Utah, Washington,
Illinois, Indiana, Michigan, North Dakota, Ohio, Alabama, Kentucky, Louisiana, Mississippi, North
Carolina, Oklahoma, Tennessee, and Texas monitor all Schedule II, III, IV, and V controlled substances.
See Drug Schedules Monitored, ALLIANCE OF STATES WITH PRESCRIPTION MONITORING PROGRAMS,
http://www.pmpalliance.org/content/drug-schedules-monitored (last visited June 12, 2011).
Pennsylvania’s prescription monitoring program includes only Schedule II controlled substances. Id.
Maine, Vermont, Arizona, California, New Mexico, Nevada, Oregon, Wyoming, Iowa, Kansas,
Minnesota, South Dakota, Florida, South Carolina, Virginia, and New Jersey collect data on all
Schedule II, III, and IV drugs. Id.
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entire schedule.9 Additionally, the required frequency for updating
prescription information in the database ranges from daily to biweekly to monthly.10 The individuals and entities permitted to
request patient prescription data also varies among the states.11 Some
states allow prescribers, pharmacists, pharmacies, law enforcement,
licensing boards, and patients to request information, while other
states limit these requests to law enforcement only.12 The Alliance of
States with Prescription Monitoring Programs offers model
legislation on its website.13
The nationwide push to implement prescription monitoring
programs has resulted in funding incentives provided by both the
Federal government and private companies for states with
programs.14 Funding is available to plan for, implement, or enhance
an existing prescription monitoring program.15 Both the Department
of Health and Human Services and the Department of Justice offer
grant programs.16 However, these programs only fund state
prescription monitoring programs that comply with certain standards,
such as including all Schedule II, III, IV, and V controlled
9. Particularly, many states specifically include Carisoprodol, a muscle relaxant commonly known
as SOMA, in the monitoring program. See Drug Schedules Monitored, supra note 8; J.A. Fass,
Carisprodol Legal Status and Patterns of Abuse, 44 ANNALS OF PHARMACOTHERAPY 1962 (2010).
Carisoprodol is not a controlled substance under federal law, but Georgia lists it as a Schedule IV
controlled substance. Compare 21 C.F.R. § 1308.14 (2009) with GA. COMP R. & REGS. 480-34-.01
(1996).
10. See PMP Data Collection Frequency, ALLIANCE OF STATES WITH PRESCRIPTION MONITORING
PROGRAMS, http://www.pmpalliance.org/content/pmp-data-collection-frequency (last visited June 12,
2011).
11. See Who is Authorized to Request Patient Prescription Data?, ALLIANCE OF STATES WITH
PRESCRIPTION MONITORING PROGRAMS, http://www.pmpalliance.org/content/who-authorized-requestpatient-prescription-data (last visited June 12, 2011).
12. Pennsylvania restricts patient prescription data requests to law enforcement only, while
Massachusetts allows prescribers, pharmacists, pharmacies, law enforcement, and patients to request
patient prescription information. Id.
13. See Prescription Monitoring Program Model Act 2010 Revision, ALLIANCE OF STATES WITH
PRESCRIPTION
MONITORING
PROGRAMS,
http://www.pmpalliance.org/pdf/PMPModelActFinal20100628.pdf (last visited June 12, 2011).
14. See Funding, ALLIANCE OF STATES WITH PRESCRIPTION MONITORING PROGRAMS,
http://www.pmpalliance.org/content/funding (last visited June 12, 2011).
15. Id.
16. See Harold Rogers Prescription Drug Monitoring Program FY 2011 Competitive Grant
Announcement, U.S. Department of Justice, OMB No. 1121-0329, available at
http://www.ojp.usdoj.gov/BJA/grant/11PDMPsol.pdf; National All Schedules Prescription Electronic
Reporting Act (NASPER) of 2005 Program Grants, U.S. Department of Health and Human Services,
available at http://www.pmpalliance.org/pdf/FY-2011-NASPER-RFA.pdf.
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substances, sharing data with other states and the federal government,
and ensuring patient privacy.17 These programs also do not provide
100% of the funds necessary to plan, implement, and maintain
prescription monitoring programs.18
The beginning of the 2011 legislative session looked hopeful for
prescription monitoring legislation in Georgia with bills introduced in
both chambers.19 Even the director of the White House Office of
National Drug Control Policy—”the White House Drug Czar”—
expressed his support for Georgia’s efforts.20 Simultaneously,
however, controversy arose surrounding Florida’s prescription drug
monitoring program.21 Florida’s Governor Rick Scott is opposed to
the database because he believes it is an invasion of privacy and puts
taxpayers “on the hook” for a program that was not supposed to
require state funding. 22 Despite the controversy in Florida, the
Georgia General Assembly passed SB 36, authorizing the creation of
a prescription monitoring database.
Bill Tracking of SB 36
Consideration and Passage by the Senate
Senators Buddy Carter (R-1st), Renee Unterman (R-45th), Greg
Goggans (R-7th), William Ligon, Jr. (R-3rd), and Charlie Bethel (R54th) sponsored SB 36.23 The Senate read the bill for the first time on
17. “To be eligible for a NASPER grant, state programs must track drugs that fall under schedules II,
III, and IV of the Controlled Substances Act, and must adhere to certain privacy, reporting, and
interoperability requirements.” Digest for HR 5710, 111th Congress, 2d Sess. (U.S. 2010), available at
http://www.gop.gov/bill/111/2/hr5710.
18. Harold Rogers funding provides up to $50,000 for planning programs and up to $400,000 for
implementation or enhancement of programs. See Harold Rogers Prescription Drug Monitoring Program
FY 2011 Competitive Grant Announcement, supra note 16. NASPER awards $21,593–$112,398 to
states with compliant prescription monitoring programs. See National All Schedules Prescription
Electronic Reporting Act (NASPER) of 2005 Program Grants, supra note 16.
19. See HB 184, as introduced, 2011 Ga. Gen. Assem.; SB 36, as introduced, 2011 Ga. Gen. Assem.
20. Gil Kerlikowske, director of the White House Office of National Drug Control Policy, pointed
out that Florida’s crackdown will force pill mills to look elsewhere, like neighboring Georgia. Carrie
Teegardin, Database Could Flag Drug Abusers, ATLANTA J.-CONST., Feb. 18, 2011, at B1.
21. Janet Zink, Fight is on to Save Drug Monitoring Database, MIAMI HERALD, Mar. 14, 2011, at
A3,
available
at
http://www.miamiherald.com/2011/03/14/2115149/fight-is-on-to-save-drugmonitoring.html.
22. Id.
23. SB 36, as introduced, 2011 Ga. Gen. Assem.
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February 1, 2011.24 Lieutenant Govenor Casey Cagle (R) assigned it
to the Health and Human Services Committee.25
The bill, as originally introduced, provided “for the establishment
of a program to monitor the prescribing and dispensing of Schedule
II, III, IV, and V controlled substances.”26 The bill modified the
definitions listed in Code section 16-13-21 by adding definitions of
“addiction,”27 “board,”28 “patient,”29 “prescriber,”30 “Schedule II, III,
IV, or V controlled substances,”31 and “tolerance”32 and altering the
definitions of “bureau,”33 “dependency,”34 and “dispenser.”35 The bill
also required dispensers to submit thirteen specific pieces of
information regarding the dispensing of such controlled substances,36
provided for the confidentiality of information in the database except
for specific circumstances, and provided for penalties for misuse of
the data.37 The bill also established an Electronic Database Review
Advisory Committee (Advisory Committee).38 The Advisory
Committee and other privacy protections such as the penalties for
misuse of the data were included in the bill to address the privacy
concerns that had prevented the bill from being passed the previous
two years.39

24. State of Georgia Final Composite Status Sheet, SB 36, May 24, 2011.
25. Id.
26. SB 36, as introduced, p. 1, ln. 2–3, 2011 Ga. Gen. Assem.
27. Id. at p. 1, ln. 18–23.
28. Id. at p. 2, ln. 34–35.
29. Id. at p. 5, ln. 156–57.
30. Id. at p. 6, ln. 183–86.
31. Id. at p. 6, ln. 191–94.
32. SB 36, as introduced, p. 6, ln. 198–201, 2011 Ga. Gen. Assem.
33. Id. at p. 2, ln. 36–37 (changing the definition from “Drug Enforcement Administration, United
States Department of Justice, or its successor agency,” to “Georgia Bureau of Investigation”).
34. SB 36, as introduced, p. 2–3, ln. 61–71, 2011 Ga. Gen. Assem.
35. Id. at p. 3, ln. 79–93.
36. Id. at p. 8, ln. 240–59 (including the DEA permit number or dispenser identification number, the
date the prescription was dispensed, the prescription serial number, if the prescription is new or a refill,
the National Drug Code for the dispensed drug, the quantity and strength dispensed, the number of days
supply of the drug, the patient’s name, the patient’s address, the patient’s date of birth, the approved
prescriber identification number or the prescriber’s DEA permit number, the date the prescription was
issued by the prescriber, and “other data elements consistent with standards established by the American
Society for Automation in Pharmacy, if designated by regulations of the board”).
37. Id. at p. 1, ln. 3–9.
38. Id. at p. 1, ln. 6–8.
39. Carter Interview, supra note 1.
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The Health and Human Services Committee offered a substitute to
SB 36.40 The substitute revised Code section 16-13-21 to define a
“dispenser” as a person that dispenses Schedule II, III, IV, or V
controlled substances instead of one that delivers such controlled
substances.41 The substitute also changed Code section 16-13-21 to
include clinics as a health care facility not covered under the
definition of “dispenser” and expanded the type of care institutional
pharmacies not considered “dispensers” provide from “inpatient” to
“patient.”42 The Committee substitute also removed language in
Code section 16-13-58 that would have allowed the State Board of
Pharmacy (Pharmacy Board) to fund grants to dispensers to cover
costs for dedicated equipment and software used to comply with the
reporting requirements from “funds from the disposition of forfeited
property.”43
Under Code section 16-13-60, the Committee substitute modified
to whom the Pharmacy Board will be authorized to provide
prescription information from the database.44 The substitute allowed
for the Pharmacy Board to provide information to officials “upon
receipt of a subpoena issued by a court of record, located within or
outside of this state” instead of by a “superior court in compliance
with Georgia law and the Georgia Constitution.”45 The substitute also
allowed for a state agency or board to receive prescription
information only from a “subpoena issued by a superior court”
instead of from “an administrative subpoena issued by such state
agency, board, or entity which is authorized to receive such
prescription information.”46 The Committee substitute also added a
provision to Code section 16-13-60 to make clear that this bill would
not prevent the Georgia Composite Medical Board (Medical Board)
or other licensing board from being able to obtain patient medical

40. SB 36 (SCS), 2011 Ga. Gen. Assem.
41. Id. § 1, p. 3, ln. 79.
42. Id. § 1, p. 3, ln. 84–85.
43. Id. § 2, p. 7, ln. 233.
44. Compare Id. § 2, p. 9, ln. 308–09, with SB 36, as introduced, § 2, p. 9, ln. 306–07, 2011 Ga.
Gen. Assem.
45. SB 36 (SCS), § 2, p. 9, ln. 308–09, 2011 Ga. Gen. Assem.
46. Compare Id. § 2, p. 9, ln. 311, with SB 36, as introduced, § 2, p. 9, ln. 308–10, 2011 Ga. Gen.
Assem.
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information from a practitioner solely on the basis that the
practitioner had placed prescription information in the database.47
The Committee substitute established a time frame for
implementation of the database in Code section 16-13-64 by
requiring the Pharmacy Board to certify when the database is
established and to post a notice of the certification on the its
website.48 Dispensers would then have 30 days to begin submitting
prescription information to the Pharmacy Board.49
The Health and Human Services Committee favorably reported its
substitute on February 17, 2011, and the bill was read on the Senate
floor for the second time on February 22, 2011.50 The bill was then
read for the third time on February 23, 2011,51 and the Senate passed
the Committee substitute of SB 36 by a vote of 49 to 6 on the same
day.52
Consideration and Passage by the House
The bill was first introduced to the House on February 24, 2011.53
The bill was read for the second time on February 28, 2011.54
Speaker of the House David Ralston (R-7th) assigned it to the House
Committee on Judiciary Non-Civil.55
The House Committee on Judiciary Non-Civil offered a House
Committee substitute that made several changes to the version that
the Senate passed.56 The Committee substitute changed the definition
of “security paper,” required that all hard copy prescriptions be on
security paper, required identification to pick up certain prescriptions,
and limited the units of Schedule II through IV drugs which may be
obtained with the use of a single prescription to sixty units.57
47.
48.
49.
50.
51.
52.
53.

SB 36 (SCS), § 2, p. 10, ln. 335, 2011 Ga. Gen. Assem.
Id. § 2, p. 11, ln. 385.
Id. § 2, p. 11, ln. 387.
State of Georgia Final Composite Status Sheet, SB 36, May 24, 2011.
Id.
Georgia State Senate Voting Record, SB 36 (Feb. 23, 2011).
Video Recording of House Proceedings, Feb. 24, 2011 at 19 min., 14 sec. (remarks by Speaker
of
the
House
David
Ralston
(R-7th),
http://mediam1.gpb.org/ga/leg/2011/ga-leghouse_022411_AM.wmv [hereinafter House First Reader Video].
54. State of Georgia Final Composite Status Sheet, SB 36, May 24, 2011.
55. Id.
56. SB 36 (HCS), 2011 Ga. Gen. Assem.
57. Compare SB 36 (HCS), p. 1, ln. 11–16, 2011 Ga. Gen. Assem. with SB 36, as passed Senate,
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In the House Committee on Judiciary Non-Civil hearing,
Representative Ed Setzler (R-35th) summarized the reasons for the
amendments.58 First, there was a concern that privacy was not being
adequately protected.59 Also, some of the amendments were made to
“clean up language where administrative subpoenas perhaps were a
little looser in the bill’s language . . . than they should have been,”
and other amendments were made to restrict the ability of other states
to access the database.60 The subcommittee also proposed
amendments that would have changed the drugs tracked by the
database to Schedule II drugs along with an enumerated list as
opposed to the original Schedule II, III, IV, and V drugs.61 These
amendments were later overridden by a Committee hearing
amendment which, limited coverage to Schedule II, III, IV, and V
drugs.62
The subcommittee also introduced an amendment to change the
requirements of any entity that has access to the database to have
“security measures that are substantially equivalent” to those of the
Pharmacy Board.63 This was meant to provide more security than the
Senate bill’s requirement that the entity “maintain security
procedures consistent with the size and sophistication of the
organization.”64 Representative Setzler (R-35th) recognized that, “as
a powerful thing, [this bill] has to be adequately shackled.”65
The substitute as recommended by the House Committee on
Judiciary Non-Civil made several other changes to the bill passed by
the Senate. It added a definition of “agency” to the definitions in
Code section 16-13-21 and defined it to mean the Georgia Drugs and
Narcotics Agency.66 The Committee substitute also amended Code
section 16-13-59 to refer to the “agency” instead of the “board,” thus
p.1, ln. 1–10, 2011 Ga. Gen. Assem.
58. House Committee Video, supra note 5 at 14 min., 48 sec. (remarks by Rep. Ed Setzler (R-35th)).
59. Id.
60. Id.
61. House Committee Video, supra note 5, at 18 min., 58 sec. (remarks by Rep. Ed Setzler (R35th)).
62. Id. at 52 min., 28 sec. (remarks by Rep. Edward Lindsey (R-54th)) (Rep. Lindsey offering his
amendment).
63. Id. at 18 min., 58 sec. (remarks by Rep. Ed Setzler (R-35th)).
64. Id.
65. Id.
66. SB 36 (HCS), § 1, p. 2, ln. 37, 2011 Ga. Gen. Assem.

Published by Reading Room, 2011

9

Georgia State University Law Review, Vol. 28, Iss. 1 [2011], Art. 15

278

GEORGIA STATE UNIVERSITY LAW REVIEW

[Vol. 28:1

requiring dispensers to send information regarding each prescription
filled to the Georgia Drugs and Narcotics Agency (Agency) instead
of the Board.67 The Committee substitute also changed the definition
of a “dispenser” to one that delivers a drug instead of one that
dispenses, going back to the definition in the bill as originally
introduced.68 Also in the definitions section, “veterinarian” was
removed from the definition of a “practitioner.”69 To further prevent
other states and the federal government from accessing the database,
the Committee extended the reach of new Code section 16-13-58(a)
to prohibit “the board, agency, [or] any other state entity” from
accepting “a grant that requires as a condition of the grant any
sharing of information that is inconsistent with this part.”70 The
Committee also modified Code section 16-13-58 by adding back in
the ability for the Agency to provide funds from the disposition of
forfeited property to dispensers for covering the costs of equipment
and software.71 The Committee also added in two more pieces of
information dispensers would need to submit to the Agency for each
prescription purchase—the gender of the patient and the method of
payment.72
To further protect the privacy of the data, the Committee changed
the amount of time that the Agency could keep the identifying
prescription information in the electronic database from two years to
one year.73 The Committee expanded the coverage of the bill by
adding in Code section 16-13-59(g), which would require
wholesalers to provide the Agency with the amounts of Schedule II,
III, IV, and V controlled substances that it ships to each dispenser in
the state.74 However, the Committee also added Code section 16-1365(b), which made clear that this bill would not cover over-thecounter Schedule V controlled substances.75 The Committee
substitute also limited those with whom the Agency could provide
67.
68.
69.
70.
71.
72.
73.
74.
75.

Id. § 2, p. 9, ln. 278–309.
Id. § 1, p. 3, ln. 88.
Id. § 1, p. 6, ln. 176.
Id. § 2, p. 7–8, ln. 239–44.
Id. § 2, p. 8, ln. 248–49.
SB 36 (HCS), § 2, p. 8, ln. 272–73, 2011 Ga. Gen. Assem.
Id. § 2, p. 9, ln. 296–300.
Id. § 2, p. 9, ln. 305–09.
Id. § 2, p. 13, ln. 432–34.
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information from the database. Besides dispensers, patients, and
prescribers, the Agency would be allowed to provide database
information to local, state, or federal law enforcement pursuant to a
search warrant and to the Agency or Medical Board upon the
issuance of an administrative subpoena issued by a Georgia state
administrative law judge.76 Further protecting the privacy of Georgia
prescription drug purchasers, the bill also removed the provision in
the Senate’s version of the bill that would allow the Pharmacy Board
to prepare a plan to share database information with other states.77
One concern of the bill’s sponsor, Senator Buddy Carter (R-1st),
was to make sure the patients that truly need medication can still get
it.78 To address this concern, the Committee amended the bill to
expand Code section 16-13-62 to make clear that nothing in the bill
should “impede, impair, or limit a prescriber from prescribing pain
medication in accordance with the pain management guidelines
developed and adopted by the Georgia Composite Medical Board.”79
Other changes included removing the requirement of posting the
certification of the database on the Pharmacy Board’s website and the
requirement that dispensers begin to submit prescription information
within thirty days of such posting.80
To protect the privacy of Georgia residents’ data, the Committee
substitute provided even harsher penalties for abuse of the database
and the information contained within.81 Additionally, amendments to
Code section 16-13-64 increased the punishment for a dispenser
knowingly and intentionally failing to submit prescription
information to the database from a misdemeanor to a felony and
increased the possible prison time to not less than one year and the
fine limit to $50,000.82 The substitute extended prison time to at least
one year for database breaches by both persons authorized to access
76. Id. § 2, p. 10, ln. 329–32.
77. Compare SB 36, as passed Senate, § 2, p. 10, ln. 319–22, 2011 Ga. Gen. Assem., with SB 36
(HCS), § 2, p. 13, ln. 333–40, 2011 Ga. Gen. Assem. (removing O.C.G.A. § 11-12-13(e)).
78. House Committee Video, supra note 5, at 26 min., 06 sec. (remarks by Sen. Buddy Carter (R1st)).
79. SB 36 (HCS), § 2, p. 12, ln. 385–87, 2011 Ga. Gen. Assembly.
80. Compare SB 36, as passed Senate, § 2, p. 12–13, ln. 385–388, 2011 Ga. Gen. Assem., with SB
36 (HCS), § 2, p. 12, ln. 396–402, 2011 Ga. Gen. Assem. (removing proposed O.C.G.A. § 16-13-64(a)).
81. House Committee Video, supra note 5, at 12 min., 55 sec. (remarks by Sen. Buddy Carter (R1st)).
82. SB 36 (HCS), § 2, p. 12, ln. 396–402, 2011 Ga. Gen. Assem.
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the database and anyone who obtains, attempts to obtain, or discloses
database information under false pretenses.83 Anyone who would use
the information in the database for commercial advantage, personal
gain, or malicious harm would be punished by a prison term of not
less than two years.84
To further reign in the influx of drug seekers from other states and
the rise of pill mills in Georgia, the Committee substitute made
changes to how prescriptions are written. First, it added sections 3, 4,
and 5, which defined what security paper could be used for
prescriptions85 and would require all hard copy prescriptions to be
written on security paper.86 Second, the Committee substitute added
Code section 26-4-80.2, which prevents pharmacists from filling
prescriptions for more than sixty units of any drug in Schedules II,
III, or IV.87
With these changes, the House Committee on Judiciary Non-Civil
favorably reported the Committee substitute on March 28, 2011.88
The bill was postponed on March 30, 2011, but then read for the third
time and debated on March 31, 2011.89 Despite concerns about
privacy and funding voiced by opponents of the bill during the House
floor debate, the bill passed the House by a vote of 117 to 45 on
March 31, 2011.90 The bill was then sent back to the Senate to
resolve the differences between the House and Senate versions of the
bill.91

83. Id. § 2, p. 12, ln. 410–18.
84. Id. § 2, p. 13, ln. 419–23.
85. Id. § 2, p. 13, ln. 439–55 (defining “security paper” as “a prescription pad or paper that has been
approved by the board for use and contains the following characteristics: (A) One or more industry
recognized features designed to prevent unauthorized copying of a completed or blank prescription
form; (B) One or more industry recognized features designed to prevent the erasure or modification of
information written on the prescription form by the practitioner; and (C) One or more industry
recognized features designed to prevent the use of counterfeit prescription forms”).
86. Id. § 2–5.
87. Id. § 5, p. 15, ln. 502–05.
88. State of Georgia Final Composite Status Sheet, SB 36, May 24, 2011.
89. Id.
90. Georgia House of Representatives Voting Record, SB 36 (Mar. 31, 2011).
91. State of Georgia Final Composite Status Sheet, SB 36, May 24, 2011.
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Senate Amendment
The Senate took up the changes made by the House on April 14,
2011.92 Senator Carter offered a floor amendment to the House
Committee substitute.93 The amendment removed the definition of
“Wholesalers”94 and the wholesalers’ requirement to report the
quantity of Schedule II, III, IV, and V controlled substances shipped
to dispensers from the House version of the bill.95 The amendment
added the consumer member that the Governor appoints to the
Pharmacy Board pursuant to Code section 26-4-21 as the tenth
member to the Advisory Committee.96 The amendment also removed
the requirement that pharmacists copy the identification document of
persons picking up prescriptions for other people.97 Senator Carter’s
amendment also limited the requirement for security paper for
prescriptions to Schedule II controlled substances.98 The amendment
also removed the sixty unit limit on prescriptions pharmacists filling
Schedule II through IV controlled substances.99
The Senate agreed with the House Committee substitute as
amended by the Senate by a vote of 53–3, and the House agreed to
Senate’s changes 131–32 on April 14, 2011.100 The Senate then sent
the bill to the Governor on April 19, 2011.101 Governor Nathan Deal
signed the bill into law on May 13, 2011.102
The Act
The Act amends Title 16 of the Official Code of Georgia
Annotated with the purpose of reducing the abuse of controlled
92. Id.
93. SB 36 (SFA), 2011 Ga. Gen. Assem.
94. Id. at p. 1, ln. 8.
95. Id. at p. 1, ln. 9.
96. Id. at p. 1, ln. 17–23.
97. Id. at p. 1–2, ln. 24–27.
98. Id. at p. 2, ln. 28–29.
99. SB 36 (SFA), p. 2, ln. 31, 2011 Ga. Gen. Assem.
100. Georgia Senate Voting Record, SB 36 (Apr. 14, 2011); Georgia House of Representatives
Voting Record, SB 36 (Apr. 14, 2011); State of Georgia Final Composite Status Sheet, SB 36, May 24,
2011.
101. Id.
102. Office of the Governor, May 13, 2011: Bills Signed by Governor Deal,
http://gov.georgia.gov/00/article/0,2086,165937316_170511855_171299722,00.html.
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substances and thereby improving the quality of healthcare. The Act
defines numerous terms by amending Code section 16-13-21.103 This
section adds definitions of “addiction,” “patient,” “prescriber,”
“schedule II, III, IV, or V controlled substance,” and “tolerance.”104
It also defines “agency” as the Georgia Drugs and Narcotics Agency,
“board” as the State Board of Pharmacy, and amends “bureau” to
mean the Georgia Bureau of Investigation.105 This section amends the
definition of “dependent” and “dispenser.”106 “Dispenser” was
amended to exclude hospital pharmacies, institutional pharmacies,
direct administration of the controlled substance, and prison
pharmacies.107
Section 2 of the Act establishes the prescription monitoring
database, provides for its security, and sets out the penalties for
breaching such security.108 First, it amends the chapter by adding Part
2 and designating Article 2 as Part 1 of Article 2.109 It adds Code
section 16-13-57, which requires the Agency to establish and
maintain “a program to electronically record into an electronic
database prescription information” related to Schedule II, III, IV, or
V controlled substances subject to funding either by the State or as
otherwise available.110 This section also clarifies that the purpose of
the Act is to reduce the abuse of controlled substances and to
improve quality of care by promoting appropriate prescribing
practices.111 It authorizes the Agency to administer the program at the
direction and oversight of the Pharmacy Board.112
103. O.C.G.A. § 16-13-21 (Supp. 2011).
104. Id.
105. “Bureau” was amended from the Drug Enforcement Administration, United States Department
of Justice. Compare O.C.G.A. § 16-13-21 (Supp. 2010) with O.C.G.A. § 16-13-21 (Supp. 2011).
106. O.C.G.A. § 16-13-21 (Supp. 2011).
107. An “institutional pharmacy” includes a nursing home, intermediate care home, personal care
home, or a hospice program, which provides care and administers the controlled substance “on the
premises of the facility.” O.C.G.A. § 16-13-21(10)(B) (Supp. 2011). “Administer” means the “direct
application of a controlled substance.” O.C.G.A. § 16-13-21(1) (Supp. 2011).
108. O.C.G.A. § 16-13-57 to -65.
109. Id.
110. The General Assembly did not appropriate the $400,000–$1.2 million to the Georgia Drugs and
Narcotics Agency to establish the database in the budget. Hunt, supra note 1. However, the section
allows the agency to seek other sources, such as federal or private funds. O.C.G.A. § 16-13-57(a) (Supp.
2011). See also supra text accompanying notes 15–18 and infra text accompanying notes 174–88.
111. Appropriate prescribing practices include “proper use of medications to treat pain and terminal
illness,” overprescribing, and duplicative prescribing. O.C.G.A. § 16-13-57(a) (Supp. 2011).
112. O.C.G.A. § 16-13-57(b) (Supp. 2011).
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Section 2 also adds Code section 16-13-58, which authorizes the
Agency to apply for funding and accept gifts in order to develop and
maintain the prescription monitoring database, so long as the
conditions of the funding do not require information sharing that is
inconsistent with this part.113 Code section 16-13-58 also grants the
Agency authority to provide funds to individual dispensers for the
purpose of compliance with this section.114 This section also makes
clear that no appropriation of state funds is required.115
The Act adds Code section 16-13-59, which establishes the
information that each dispenser must submit to the Agency for any
Schedule II, III, IV, or V controlled substance.116 The required
information includes at a minimum: Drug Enforcement Agency
(DEA) permit or dispenser facility controlled substance identification
number, date the prescription was dispensed, prescription serial
number, if the prescription is new or a refill, National Drug Code for
drug dispensed, quantity and strength dispensed, number of days
supply of the drug, patient’s name, address, date of birth, gender,
method of payment, date the prescription was issued by the
prescriber, and other data consistent with standards established by the
American Society for Automation in Pharmacy.117 Dispensers are
required to submit the required prescription information on at least a
weekly basis and at a minimum no later than ten days after the
prescription is dispensed.118 This Code section also requires that
dispensers that are temporarily unable to comply with the submission
rules notify the Pharmacy Board and the Agency.119 Additionally, the
Agency may issue a waiver to any dispenser that is unable to comply
with the reporting requirements.120 Code section 16-13-59 prohibits
the Agency from revising the required information more frequently
than annually and any such changes are effective and applicable to
113. O.C.G.A. § 16-13-58 (Supp. 2011).
114. It is likely that this clause was required for passage due to limited funds in the budget. O.C.G.A.
§ 16-13-58(b) (Supp. 2011).
115. O.C.G.A. § 16-13-58(c) (Supp. 2011).
116. O.C.G.A. § 16-13-59(a) (Supp. 2011).
117. O.C.G.A. § 16-13-59(a)(1)-(15) (Supp. 2011).
118. O.C.G.A. § 16-13-59(b) (Supp. 2011).
119. Id.
120. The waiver request must be in writing when submitted to the agency. The waiver may permit a
dispenser to submit the required prescription information by paper form or other means, so long as all of
the required information is included. O.C.G.A. § 16-13-59(c) (Supp. 2011).
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dispensers six months after they are adopted.121 The Agency is
prohibited from accessing or allowing access to any identifying
prescription information in the electronic database after one year
from its inclusion in the database.122 Additionally, the Agency is
required to promulgate rules and procedures that will “ensure that
any identifying information the agency receives from any dispenser
or reporting entity that is one year old or older is deleted or destroyed
on an ongoing basis in a timely and secure manner.”123
Section 2 of the Act adds Code section 16-13-60, which first
establishes that the prescription information submitted pursuant to
Code section 16-13-59 is confidential and exempt from open records
requirements.124 It further requires that the Agency and the Pharmacy
Board “establish and maintain strict procedures to ensure that the
privacy and confidentiality of patients, prescribers, and patient and
prescriber information collected, recorded, transmitted, and
maintained pursuant to this part are protected.”125 The permitted
disclosures are limited to: (1) authorized prescribers or dispensers of
controlled substances for the purpose of providing care to a specific
patient, (2) upon request by a patient, prescriber or dispenser where
the information concerns the requestor, (3) to local, state, or federal
law enforcement or prosecutorial officials pursuant to a search
warrant, and (4) to the Medical Board pursuant to an administrative
subpoena.126 It prohibits disclosure to any person or entity not
specified and only in accordance with HIPAA standards.127
Code section 16-13-60 allows the disclosure of de-identified
prescription information to governmental entities for statistical
research, educational, or grant application purposes.128 It also
121. O.C.G.A. § 16-13-59(d) (Supp. 2011).
122. O.C.G.A. § 16-13-59(e) (Supp. 2011).
123. Id.
124. O.C.G.A. § 16-13-60(a) (Supp. 2011); Open records laws allow interested individuals, firms,
corporations, or other entities to inspect, extract, or make copies of any public record. O.C.G.A. § 5018-70.
125. O.C.G.A. § 16-13-60(b) (Supp. 2011).
126. O.C.G.A. § 16-13-60(c) (Supp. 2011).
127. O.C.G.A. § 16-13-60(b) (Supp. 2011). The Health Insurance Portability and Accountability Act
(HIPAA) of 1996 prohibits disclosure of protected health information except under limited
circumstances. 42 U.S.C.A. § 102 (1996).
128. The disclosed prescription information must be stripped of information that “could be used to
identify prescribers or individual patients or persons who received prescriptions from dispensers.
O.C.G.A. § 16-13-60(d) (Supp. 2011).
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prohibits any person or entity permitted to receive prescription
information from subsequently providing that information to any
other person or entity unless required by court order.129 This section
requires any permissible user who directly accesses the prescription
information contained in the database to implement and maintain a
“comprehensive information security program” that includes security
measures equal to those of the Agency.130 Finally, the Act does not
modify, limit, diminish, or impliedly repeal any authority of a
licensing or regulatory board, or other entity authorized to obtain
prescription information from other sources, provided that the
Agency may release information only in accordance with this
section.131
Code section 16-13-61 creates an Electronic Database Review
Advisory Committee (Advisory Committee) to consult with and
advise the Agency on the establishment, maintenance, and operation
of the electronic prescription database.132 The Advisory Committee
will consist of ten uncompensated members each serving a three-year
term, with five members constituting a quorum.133 It will meet at
least once per year or by request of the chairperson or at least three
members.134
Section 2 adds Code section 16-13-62, which requires the Agency
to establish rules and regulations in order to implement the Act.135
Simultaneously, it prohibits the Agency from establishing policies,
rules, or regulations that limit, revise, or expand the prescription or
129. O.C.G.A. § 16-13-60(e) (Supp. 2011).
130. The comprehensive information security program must include administrative, technical, and
physical safeguards and the user must identify “foreseeable internal and external risks to the security,
confidentiality, and integrity of the personal information that could result in the unauthorized disclosure,
misuse, or other compromise of the information.” O.C.G.A. § 16-13-60(f) (Supp. 2011).
131. O.C.G.A. § 16-13-60(g) (Supp. 2011).
132. The committee will: review methods of data collection, access, and security, evaluate data to
“identify benefits and outcomes of the reviews,” and communicate with prescribers and dispensers about
the reviews and database use. O.C.G.A. § 16-13-61(a) (Supp. 2011).
133. The committee must include one representative each, from the Georgia Drugs and Narcotics
Agency, the Georgia Composite Board of Medicine, the Georgia Board of Dentistry, and the Georgia
Board of Optometry. It must also include an expert in personal privacy matters appointed by the State
Bar of Georgia and an addiction professional, a pain management specialist, an oncologist, and a
hospice representative, each appointed by the Georgia Composite Medical Board. The tenth member of
the committee must be a consumer member appointed by the Governor to the State Board of Pharmacy
under Code section 26-4-21. O.C.G.A. § 16-13-61 (Supp. 2011).
134. O.C.G.A. § 16-13-61 (Supp. 2011).
135. O.C.G.A. § 16-13-62 (Supp. 2011).

Published by Reading Room, 2011

17

Georgia State University Law Review, Vol. 28, Iss. 1 [2011], Art. 15

286

GEORGIA STATE UNIVERSITY LAW REVIEW

[Vol. 28:1

dispensing authority of any prescribers or dispensers subject to this
part, including the authority to prescribe pain medication in
accordance with the Medical Board’s pain management guidelines.136
Code section 16-13-63 was added to limit the liability of a
prescriber or dispenser, stating that they have no duty to obtain
prescription information about a patient and shall not be held civilly
liable or criminally responsible for damages or injury based on a
failure to obtain prescription information from the database.137
Section 2 adds Code section 16-13-64, which sets out penalties for
failure to submit prescription information to the database and
improper disclosure of information contained in the database.138 First,
a dispenser who knowingly and intentionally fails to submit or
submits incorrect prescription information is guilty of a felony and
faces not less than one year nor more than five years imprisonment
and a fine not to exceed $50,000 for each offense.139 Additionally,
the offense is reported to the dispenser’s licensing board.140 Second,
an individual permitted to access prescription information contained
in the database who negligently uses, releases, or discloses
information in violation of this part is guilty of a misdemeanor for the
first offense and a felony for the second offense, subject to
imprisonment for not less than one year and not more than three
years and a fine not to exceed $5,000.141 Third, an individual
permitted to access prescription information contained in the
database who knowingly obtains or discloses information in violation
of this part is guilty of a felony and faces punishment of not less than
one year but not more than five years imprisonment and a $50,000
fine.142
Under new Code section 16-13-64, any person who knowingly
obtains or discloses prescription information under false pretenses is
guilty of a felony, punishable by imprisonment for not less than one
year and not more than five years and a fine of $100,000.143 Any
136.
137.
138.
139.
140.
141.
142.
143.

Id.
O.C.G.A. § 16-13-63 (Supp. 2011).
O.C.G.A. § 16-13-64 (Supp. 2011).
O.C.G.A. § 16-13-64(a) (Supp. 2011).
Id.
O.C.G.A. § 16-13-64(b) (Supp. 2011).
O.C.G.A. § 16-13-64(c)(1) (Supp. 2011).
O.C.G.A. § 16-13-64(c)(2) (Supp. 2011).
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unauthorized person who obtains or discloses prescription
information with the intent to sell, transfer, or use the information for
commercial or personal gain or malicious harm is guilty of a felony
and faces not less than two years and not more than ten years
imprisonment and a fine not to exceed $250,000.144 This section
continues to provide a cause of action for actual damages, punitive
damages where appropriate, attorney fees, and litigation expenses to
any person injured by reason of a violation of this part.145 All
penalties in Code section 16-13-64 are intended to be cumulative of
other applicable penalties and and this section does not repeal
alternative penalties.146
New Code section 16-13-65 exempts veterinarians from the
provisions of this part and makes this part inapplicable to “any drug,
substance, or immediate precursor classified as an exempt over-thecounter Schedule V controlled substance pursuant to this chapter or
pursuant to Pharmacy Board rules established in accordance with
Code section 16-13-29.2.”147
Section 3 of the Act amends Chapter 4 of Title 26 of the Official
Code of Georgia Annotated by revising paragraph (38.5) of Code
section 26-4-5, redefining “security paper” to mean an approved
prescription pad or paper that contains industry recognized features
designed to prevent unauthorized copying, erasure or modification of
information written on the paper, and counterfeit use.148 It also
requires that any pad of security paper bears an identifying lot
number and that each page is numbered sequentially beginning with
the number one.149
Section 4 further amends Code section 26-4-80 by requiring any
person picking up a Schedule II controlled substance to present photo
identification that displays the person’s full name.150

144. O.C.G.A. § 16-13-64(c)(3) (Supp. 2011).
145. O.C.G.A. § 16-13-64(d) (Supp. 2011).
146. O.C.G.A. § 16-13-64(e) (Supp. 2011).
147. O.C.G.A. § 16-13-65 (Supp. 2011). Code section 16-13-29.2 grants the Board of Pharmacy
authority to exempt and control the sale of Schedule V controlled substances without requiring a
prescription. O.C.G.A. § 16-13-29.2 (2010).
148. O.C.G.A. § 26-4-5(38.5) (Supp. 2011).
149. Id.
150. O.C.G.A. § 26-4-80(1) (Supp. 2011).
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Section 5 of the Act adds Code section 26-4-80.1, which requires
that every hard copy prescription for any Schedule II controlled
substance be written on security paper.151 It prohibits a pharmacist
from filling a hard copy prescription for any Schedule II controlled
substance unless it is on security paper. This rule does not apply in an
emergency, however.152 The section requires that a hard copy of an
electronic Schedule II controlled substance prescription drug order
given directly to the patient be manually signed and on security paper
approved under Code section 26-4-5.153 Prescribers must implement
proper safeguards to prevent theft or unauthorized use of security
paper and report any theft or unauthorized use to appropriate
authorities.154 This section also requires vendors to get approval by
the Pharmacy Board for their security paper prior to sale or
marketing in Georgia.155 The Pharmacy Board also must create a seal
of approval confirming that security paper contains the required
industry recognized characteristics listed in paragraph (38.5) of Code
section 26-4-5 and the seal must be affixed to all security paper used
in Georgia.156 The Pharmacy Board is permitted to adopt rules
necessary to administer this Code section.157 Finally, this Code
section does not apply to prescriptions transmitted to the pharmacy
through facsimile, telephone, or electronic means, nor for
prescriptions written for hospital inpatients or outpatients, nursing
home residents, mental health facility inpatients or residents, or
prisoners incarcerated in a local, state, or federal correctional facility,
when the prescription is written into the patient’s medical record, the
order is given to the pharmacy directly, and the patient has no
opportunity to handle the written order.158

151.
152.
153.
154.
155.
156.
157.
158.

This provision is effective October 11, 2011. O.C.G.A. § 26-4-80.1(a) (Supp. 2011).
O.C.G.A. § 26-4-80.1(b) (Supp. 2011).
O.C.G.A. § 26-4-80.1(c) (Supp. 2011).
O.C.G.A. § 26-4-80.1(d) (Supp. 2011).
O.C.G.A. § 26-4-80.1(e) (Supp. 2011).
O.C.G.A. § 26-4-80.1(f) (Supp. 2011).
O.C.G.A. § 26-4-80.1(g) (Supp. 2011).
O.C.G.A. § 26-4-80.1(h) (Supp. 2011).
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Analysis
Two significant areas of contention during the drafting of the Act
were privacy and funding.159 The two issues are intertwined, as the
Act’s strict privacy protections were necessary to ensure its passage,
yet may preclude available federal funding grants. Because the
General Assembly did not allocate the funds needed to create the
database, outside sources are the only available means to fund the
project.160 The Act, however, may not meet federal grant
requirements due to the privacy restrictions, so limited funding
options are available and may ultimately prevent creation of the
database.161
Privacy
Privacy remains an issue for the Act going forward, despite
proponents’ efforts to address the concerns during the legislative
process.162 The Act aims to protect privacy in three ways: regulating
who can access the data; creating an Advisory Committee to manage
the database’s security; and providing substantial penalties for
violating the access protocols of the database information.
First, the Act limits who has access to the data.163 It permits
disclosure of patient prescription information only to authorized
prescribers or dispensers for providing care to a specific patient, upon
request by a patient, prescriber, or dispenser about whom the
information concerns, to law enforcement with a search warrant, or to
the Agency or Medical Board with an administrative subpoena.164
The Act does not permit sharing of patient prescription information
with other states or the Federal government except with a
subpoena.165 Although passage of the Act was contingent on the

159. See Carter Interview supra note 1.
160. See Hunt, supra note 1.
161. Id.
162. See Carter Interview supra note 1; House Committee Video, supra note 5, at 14 min., 48 sec.
(remarks by Rep. Ed Setzler (R-35th)).
163. O.C.G.A. § 16-13-60(c) (Supp. 2011).
164. Id.
165. Hunt, supra note 1.
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inclusion of these strict privacy provisions, the provisions also limit
available sources of funding.166
The second privacy concern raised during the development of the
Act was that of security breaches that might reveal database
information to unauthorized third parties.167 As Representative
Christian Coomer (R-14th) noted, the Act “creates a very target-rich
environment for bad actors to try to go and steal that information.”168
Representative Coomer also cited recent data breaches of the Sony
Corporation’s PlayStation user database that revealed 70 million
users’ sensitive data.169 Proponents of the Act noted such security
concerns,170 and through the addition of Code section 16-13-61, the
Act establishes an Advisory Committee that would monitor security
and access of the database.171 Until the Advisory Committee’s
regulations are in place, there is no way to determine whether the
security placed on the database by the Advisory Committee’s
regulations will be more effective than those of Sony’s breached
database.
To further address security and privacy concerns, proponents of
the Act added substantial penalties for those guilty of unauthorized
access to the database or unauthorized dissemination of database
information.172 Classifying violations as felonies with punishments
up to $250,000 in fines and up to ten years in prison should serve to
deter security breaches.173
Funding
Although the Act establishes a prescription monitoring database,
its creation, implementation, and maintenance will require a
166. Id; see also text accompanying notes 174–88.
167. House First Reader Video, supra note 53 at 1 hr., 52 min., 47 sec. (remarks by Rep. Christian
Coomer (R-14th)), http://mediam1.gpb.org/ga/leg/2011/ga-leg-house_033111_PM2.wmv.
168. Telephone Interview with Rep. Christian Coomer (R-14th) (May 11, 2011) [hereinafter Coomer
Interview] (on file with the Georgia State University Law Review).
169. Id.
170. House Committee Video, supra note 5, at 14 min., 48 sec. (remarks by Rep. Ed Setzler (R35th)).
171. O.C.G.A. § 16-13-61 (Supp. 2011).
172. House Committee Video, supra note 5, at 13 min., 00 sec. (remarks by Sen. Buddy Carter (R1st)).
173. O.C.G.A. § 16-13-64 (Supp. 2011).
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significant amount of money.174 Since the legislature did not provide
state funding for the database, the Agency will have to look to federal
or private funding to implement it.175 Federal funding is available
through the National All Schedules Prescription Electronic Reporting
Act of 2005 (NASPER) so long as the state law meets the federal
requirements.176 In order to receive funding through NASPER, a state
prescription monitoring database must require reporting of all
Schedule II, III, and IV controlled substances.177 The Act fulfills this
requirement by including all Schedule II, III, IV, and V controlled
substances.178
One goal of NASPER funding is to incentivize states to share
information with each other because it is common for addicts or drug
dealers to cross state lines to fill prescriptions.179 If neighboring
states do not share information with each other, law enforcement is
unable to stop this practice. However, as Representative Coomer
pointed out, if the Pharmacy Board receives federal funding from a
grant established by NASPER, part of the requirement of doing so is
opening the database up to all other states that have similar programs
in place.180 Because the Act prohibits disclosure to any unauthorized
entity, which includes neighboring states without a search warrant, it
is unlikely that Georgia’s prescription monitoring program will
qualify for the grant.181 Furthermore, the Act prevents the Pharmacy
Board, Agency, and any state entity from accepting a grant to fund
the database “that requires as a condition of the grant any sharing of
information that is inconsistent with this part.”182 Even if Georgia
does qualify for federal aid, the deadline for 2011 grant applications

174. Estimates range from $400,000 to $1.2 million. Hunt, supra note 1.
175. Id.
176. National All Schedules Prescription Electronic Reporting Act of 2005, Pub. L. No. 109-60, 119
Stat. 1979 (2005); See also Prescription Drug Monitoring Expands, 38 No.1 Controlled Substance
Handbook Newsletter 4, July, 2009.
177. See Prescription Drug Monitoring Expands, supra note 176.
178. O.C.G.A. § 16-13-57(a) (Supp. 2011).
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has passed.183 Nevertheless, the Agency is moving ahead with its
application for the federal money.184
Private funding may also be available.185 In fact, the drug company
that manufactures Oxycontin offered $1 million to fund Florida’s
prescription monitoring database.186 Pharmaceutical companies have
an incentive to aid states in setting up prescription drug monitoring
programs.187 These companies seek to keep their products on the
shelves so that patients in need have access to them.188
Currently, it is unclear when or if Georgia’s prescription drug
monitoring program will be up and running. If the Agency is
successful in obtaining funding, the program may be operational by
2013.189 If not, the program may just be a great idea that never comes
to life.
Jared Bruff & Megan Daugherty
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